Leukemia M5 is acute myeloid leukemia type M5, or acute monocytic leukemia, which is a type of acute myeloid leukemia.
Acute leukemia type M5 is not the most severe. The prognosis for acute lymphoblastic leukemia in adults is mostly poor. The prognosis for the M3 type of acute myeloid leukemia is good and mostly curable, and the prognosis for the M5 type is relatively poor, with an approximate cure rate of 30% to 40%.
The clinical evaluation of leukemia patients depends on the patient’s staging, in addition to the patient’s age at diagnosis, physical status, white blood cell count, and clinical manifestations such as anemia, fever, hemorrhage, and central nervous system invasion, as well as their cytogenetic and molecular biological features.
Currently, as cytogenetics and molecular biology continue to advance, the risk stratification of AML is divided into low-risk, intermediate-risk, and high-risk groups. There are significant differences in treatment response and overall survival in patients with AML in different risk stratifications.
Current treatment for leukemia includes induction of remission therapy and post-remission therapy, with options for consolidation chemotherapy and hematopoietic stem cell transplantation, and now cellular immunotherapy.
Also, as research into the molecular features of leukemia has advanced, many targeted agents have emerged. Therefore, a proportion of leukemias can survive disease-free for a long time with chemotherapy, so patients should not give up too soon and should cooperate with their doctors.